Evidence map›Paper›PMID 32021457›Full record

ArticleCancer management and research2020

Predictors of Survival Among Colorectal Cancer Patients in a Low Incidence Area.

Nahla Azzam, Yazed AlRuthia, Othman Alharbi, Abdulrahman Aljebreen, Majid Almadi, Maryam Alarfaj, Khalid Alsaleh, Abdulaziz Almasoud, Muhannad Alsharidah, Sarah Alseneidi and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancer management and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Nahla AzzamGastroenterology Division, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.ORCID 0000-0002-2097-289X
Yazed AlRuthiaDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.ORCID 0000-0002-0029-5924
Othman AlharbiGastroenterology Division, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Abdulrahman AljebreenGastroenterology Division, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.ORCID 0000-0001-5666-9588
Majid AlmadiGastroenterology Division, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Maryam AlarfajDepartment of Pharmaceutical Care, King Saud University Medical City, Riyadh, Saudi Arabia.
Khalid AlsalehDepartment of Hematology/Oncology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Abdulaziz AlmasoudGastroenterology Division, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.ORCID 0000-0003-2731-4395
Muhannad AlsharidahGastroenterology Division, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Sarah AlseneidiGastroenterology Division, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Fatimah AlaliGastroenterology Division, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Malak AlalwanGastroenterology Division, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
King Saud University · SAKing Saud Medical City · SAMontreal General Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer is the third most common malignancy in Saudi Arabia. The best therapeutic regimen for colorectal cancer is a matter of ongoing debate and data on its treatment in Saudi Arabia are limited. PURPOSE: The objective of this study was to explore the predictors of survival and to compare the risk of mortality among colorectal cancer patients treated with different therapeutic modalities. PATIENTS AND

methodsThe study utilized data from the electronic colorectal cancer registry of a university-affiliated tertiary care hospital. The Kaplan-Meier survival analysis was used to estimate the survival rates over 36 months of follow-up across rectal and colon cancer patients as well as different sociodemographic and medical characteristics. Bivariate and multiple Cox proportional-hazards regressions were conducted to estimate the risk of mortality among rectal and colon cancer patients undergoing different treatments.

resultsThe number of patients in the registry who were followed up for 36 months was 143 patients. The majority of patients had colon cancer (74.13%). Rectal cancer patients had generally better survival estimates compared to their colon cancer counterparts. Colon cancer patients treated with chemotherapy had a significantly lower risk of mortality controlling for the use of surgery, radiotherapy, and other variables including age, gender, stage of cancer, and family history of colorectal cancer (HR=0.33;

conclusionThe findings of this study highlight the value of chemotherapy in managing colon cancer patients.

Indexed as

chemotherapycolorectal cancerSaudi Arabiasurgerysurvival

Identifiers

PMID32021457
PMCPMC6982433
OpenAlexW2998979114

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.